Clinical impact of occult hepatitis B virus infection in immunosuppressed patients

doi:10.4254/wjh.v6.i6.384

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 6

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7964)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series.

Item

Count

PDF

630

WORD

423

HTML

4548

Figures (1-3)

295

Sum=5896

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1014

Download

1054

Sum=2068

Jun 27, 2014 (publication date) through Dec 23, 2024

Times Cited of This Article

Times Cited (45)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Jun 27, 2014; 6(6): 384-393
Published online Jun 27, 2014. doi: 10.4254/wjh.v6.i6.384

Open in New Tab Full Size Figure Download Figure

Figure 1 Virological and biochemical dynamics of reactivation of occult hepatitis B infection. HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBsAg: Hepatitis B surface antigen.

Open in New Tab Full Size Figure Download Figure

Figure 2 Management of occult hepatitis B infection in hematological and rheumatological diseases and in solid cancers. ¹Entecavir instead of Lamivudine, when appropriate. HBsAg: Hepatitis B surface antigen; ALT: Alanine aminotransferase; Anti-HBc: Hepatitis B core antigen; TNF-α: Tumor necrosis factors-alpha.

Open in New Tab Full Size Figure Download Figure

Figure 3 Management of occult hepatitis B infection in anti-human immunodeficiency virus-positive subjects. HCV: Hepatitis C virus; ALT: Alanine aminotransferase; HBV: Hepatitis B virus; HAART: Highly active antiretroviral therapy; HBsAg: Hepatitis B surface antigen.

Citation: Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol 2014; 6(6): 384-393
URL: https://www.wjgnet.com/1948-5182/full/v6/i6/384.htm
DOI: https://dx.doi.org/10.4254/wjh.v6.i6.384